KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2025)

CRISPR Therapeutics AG's EBT Margin history spans 11 years, with the latest figure at 15046.18% for Q4 2025.

  • For Q4 2025, EBT Margin fell 1607525.0% year-over-year to 15046.18%; the TTM value through Dec 2025 reached 16466.24%, down 1657674.0%, while the annual FY2025 figure was 16466.24%, 1657674.0% down from the prior year.
  • EBT Margin for Q4 2025 was 15046.18% at CRISPR Therapeutics AG, down from 11903.49% in the prior quarter.
  • Across five years, EBT Margin topped out at 1029.07% in Q4 2024 and bottomed at 2022866.67% in Q4 2022.
  • The 5-year median for EBT Margin is 15503.4% (2021), against an average of 131848.02%.
  • The largest annual shift saw EBT Margin crashed -202175417bps in 2022 before it surged 202300119bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 1112.5% in 2021, then crashed by -181731bps to 2022866.67% in 2022, then surged by 100bps to 134.52% in 2023, then skyrocketed by 665bps to 1029.07% in 2024, then tumbled by -1562bps to 15046.18% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's EBT Margin are 15046.18% (Q4 2025), 11903.49% (Q3 2025), and 23235.09% (Q2 2025).